TransMedics Group, Inc. (TMDX)

Market Cap	4.44B +97.5%
Revenue (ttm)	566.35M +41.2%
Net Income	91.77M +181.2%
EPS	2.54 +170.7%
Shares Out	34.17M
PE Ratio	51.20
Forward PE	50.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	434,884
Open	127.50
Previous Close	128.52
Day's Range	127.50 - 132.22
52-Week Range	62.07 - 156.00
Beta	1.98
Analysts	Buy
Price Target	144.25 (+11.1%)
Earnings Date	Feb 24, 2026

About TMDX

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung trans...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 2, 2019
• Employees: 728
• Stock Exchange: NASDAQ
• Ticker Symbol: TMDX
• Website: https://www.transmedics.com

Analyst Summary

According to 8 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price target is $144.25, which is an increase of 11.10% from the latest price.

Price Target

$144.25

(11.10% upside)

Analyst Consensus: Buy